FDA approves new treatment for hospital-acquired bacterial pneumonia

Alia Paavola - Print  | 

The FDA approved Zerbaxa June 3 for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Zerbaxa, a combination of cephalosporin ceftolozane and tazobactam, was initially approved in 2014 to treat intra-abdominal infections and complicated urinary tract infections.

The new indication for the drug, given by injection, was demonstrated in a double-blind study that compared the drug to another antibacterial drug. Mortality and cure rates for Zerbaxa were similar to the treatment used as a comparison.

Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia are life-threatening pulmonary infections that often affect already vulnerable patients. They are also the second most common type of hospital-acquired infection in the U.S.

Zerbaxa is manufactured by Merck.

More articles on pharmacy:
Viewpoint: The $2.1M drug price record won't last long
Mallinckrodt to spin off generics unit
Pharma exec Martin Shkreli sues Retrophin directors from prison

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.